ReviewFrontiers in immunology2022

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.

Yanxin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.